GLMD

Bullish

Galmed, Tissue Dynamics report preclinical cardiac fibrosis data

Galmed Pharmaceuticals and Tissue Dynamics announced positive preclinical results for a combination therapy involving Aramchol Meglumine and a selecti...

Investing.com 5 mins ago 0

Bullish

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

Tissue Dynamics and Galmed Pharmaceuticals have identified a previously unrecognized metabolic pathway responsible for cardiac fibrosis and heart fail...

PR Newswire 14 mins ago 0